Tag Archives: Afinitor®

Novartis: study shows Afinitor® reduced the risk of progression in patients with advanced nonfunctional gastrointestinal and lung NET

In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional neuroendocrine tumors of GI or lung origin are rare forms of cancer with poor prognoses and … Read the full press release

Novartis: Phase III study of Afinitor® shows significant extension of progression-free survival in advanced gastrointestinal or lung neuroendocrine tumors

Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at a major medical meeting; worldwide regulatory filings are planned for 2015 Afinitor is already … Read the full press release